LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-s

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamabFull data

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.6

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street ana

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Se

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse ev

Shares of PVH fell 21.42% in pre-market trading even after strong Q1. Gainers include CXApp, TaoWeav

Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswir

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy a

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst c

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy an

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst c

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibo

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antib

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across th

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.19) per share which beat the analyst c

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy an

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid r

Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintai

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst c

RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) o

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

  During the session on Thursday, 461 stocks hit new 52-week lows.